What if I told you 1 in 50 people who took a new medication had a "medically-attended adverse event" and the manufacturer refused to disclose what the complication was, would you take it? And what if the theoretical benefit only lasted for a 3-mo window after which time the benefit is gone? and that the FDA cleared it without any human outcomes data, would you take it? and that European regulators are not universally recommending the same medication for everyone as the CDC is? and that Drs. Ashish Jha and Mandy Cohen are making unsupported claims that it reduces hospitalizations, long-Covid, and makes you less likely to spead Covid (if the manufacturers made those same claims they could be fined by the FDA for making false marketing claims beyond it's approved indication)
That's the new Moderna Covid vaccine. FDA or Moderna (I can't tell the difference sometimes) should disclose the details of the clinical trial complication rather than keeping it secret.
Irony alert! Per #IRA, #340B discounts won't factor in manufacturers' #PartD inflation rebates. Check out @CMSGov initial thoughts on identifying 340B Rx claims.
Meanwhile, @HHSGov is currently suing manufacturers that are trying to ID 340B claims...🙄
https://t.co/ZjZInLncpL
For the first time we have been named to FORTUNE® magazine’s list of the World's Most Admired Companies!
This recognition is a result of our purpose-driven partnerships with clients, communities, and other stakeholders.
Know more: https://t.co/OAkBxstm2R
@FortuneMagazine
With the increasing trend of cyber threats in healthcare, these actionable insights can serve as a constructive guide to #healthcare and #lifesciences professionals along with others. #riskmanagement#cyberincident Tata Consultancy Services
https://t.co/R6UcTqRkAO
Proud of our "Purpose Driven Healthcare Practice" at Tata Consultancy Services and the postive impacts we are having in efforts to transform Health and Wellness HFS Research #healthcare#payers#providers#wellbeing#innnovation#valuebasedcare https://t.co/UWVc6I2rcS
Worth reading: Overview of @Walgreens $WBA U.S. strategy as it races away from its #pharmacy roots & towards #healthcare services
Per CEO Brewer: "dispensing of pharmaceuticals is not going to be our long-term growth avenue"
@HeatherLandi@FierceHealth
https://t.co/1W3eOgsG5H